Leqvio (Inclisiran Sodium) Patent Expiration, LOE Window & CMS Spending

Leqvio (Inclisiran Sodium) by Novartis: FDA Orange Book core substance LOE 2034-08-18 (last listed 2036-08-25), 0 AB generics, $20.2M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNovartis
FDA Application & PathwayN214012 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2034-08-18
Last Listed Patent or Exclusivity Date2036-08-25
Orange Book Patents (*PED Extensions)10 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$20.2M
2024 Medicare Part D Spend$14.4M
2024 Medicaid Spend$5.8M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.